Newsroom

Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades.

1 min read

Selexis SA to Present and Partner at the BIO-Europe Spring

Mar 8, 2013 1:24:38 PM

Dr. Armelle Gaussin to Present in the Cell Therapy/Regenerative Medicine Track

Geneva, Switzerland (PRWEB) March 8, 2013 – Selexis SA announced today the Company’s vice president of business development, Armelle Gaussin, PhD, will present, “Proprietary and Unique Expression System for Versatile and Ubiquitous Transgene Expression” as part of the Cell Therapy/Regenerative Medicine Track on Tuesday, March 12, 2013 at 3:30 PM at the BIO-Europe Spring 2013 Partnering Conference being held March 11 – 13, 2013 at the Centre Conventions Internacional Barcelona (CCIB), in Barcelona, Spain. The Company will be also taking part in the pre-scheduled partnering meetings.

Presentation Abstract
Selexis has developed a full expression platform based on proprietary epigenetic regulator elements, the Selexis Genetic Elements, enabling versatile and ubiquitous transgene expression in mammalian cells. This expression system has a wide range of application areas. In the cell therapy field, high and stable transgene expression is obtained in adult stem cells and also sustained upon cell differentiation both in vitro and in vivo. The platform also provides a simple, fast and reliable approach towards stable cell line development for the production of therapeutic proteins and offers a dedicated approach for difficult to express proteins.

Companies or individuals attending BIO-Europe Spring can schedule meetings with Selexis (registration required) by visiting: http://www.ebdgroup.com/bes/index.php

Topics: 2013

Featured